Skip to main content
Figure 2 | BMC Public Health

Figure 2

From: Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

Figure 2

Probabilistic sensitivity analysis. A: ICER of PHiD-CV vs no vaccine; B: ICER of PHiD-CV vs PCV-13. The diagonal grey line indicates the cost-effectiveness threshold. ICER, incremental cost-effectiveness ratio; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life year.

Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us